---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-029540"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2026-01-29T23:59:59+00:00"
generated_at: "2026-05-16T06:34:09.769669+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics names Sarah Williams as VP, Controller and PAO; CFO Lucy Day salary reduced from Apr 2026

## Summary
- Sarah Williams appointed VP, Controller and Principal Accounting Officer, effective Feb 1, 2026.
- Lucy Day remains CFO; base salary reduced to $223,600 from April 1, 2026 (current $335,400 until Mar 31).
- Williams receives annual base salary of $310,000 with target annual bonus of 30% of base.
- Day's severance eligibility reduced to 50% of plan if terminated after April 1, 2026 (non-CIC).

## SEC filing metadata
- accession: 0001193125-26-029540
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2026-01-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312526029540/0001193125-26-029540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312526029540/d84725d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-029540
- JSON: https://secwatch.observer/filing/0001193125-26-029540.json
- Plain text: https://secwatch.observer/filing/0001193125-26-029540.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.